ImmunityBio Shares Are Trading Higher After Piper Sandler Maintained a Neutral Rating on the Stock and Raised Its Price Target From $5 to $6
在派珀·桑德勒維持對該股的中性評級並將其目標股價從5美元上調至6美元之後,ImmunityBio股價走高
ImmunityBio Shares Are Trading Higher After Piper Sandler Maintained a Neutral Rating on the Stock and Raised Its Price Target From $5 to $6
在派珀·桑德勒維持對該股的中性評級並將其目標股價從5美元上調至6美元之後,ImmunityBio股價走高
使用瀏覽器的分享功能,分享給你的好友吧